Stockscreener 앱 받기
1.91
3.80%
0.07
Pharmacyte Biotech Inc 주식(PMCB)의 최신 뉴스
Pharos Energy Advances Buyback, Reduces Share Capital - TipRanks
PPBT stock touches 52-week low at $5.89 amid market challenges By Investing.com - Investing.com South Africa
Proteomics International Laboratories (ASX:PIQ) presenting at the Pitt Street Research Life Sciences Conference 2024 - Stocks Down Under
POET Technologies (CVE:PTK) Trading Up 14.6% - MarketBeat
Small Cap Stocks: Plexus, Parkmead, Proton Motor - The Armchair Trader
PDS Biotechnology: Continuing The Holding Pattern (NASDAQ:PDSB) - Seeking Alpha
Tri Locum Partners LP Trims Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Westwood Holdings Group Inc. Has $572,000 Stock Holdings in Patterson Companies, Inc. (NASDAQ:PDCO) - Defense World
Pre-IPO Zhejiang Taimei Medical Technology (PHIP Updates)Some Points Worth the Attention - Smartkarma
Texas Permanent School Fund Corp Sells 6,500 Shares of Bio-Techne Co. (NASDAQ:TECH) - Defense World
Pancreatic Cancer Market Status Analysis, Scope, Trend, Capacity and Forecast 2024-2033 - Cauverynews
PharmaCyte Biotech, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2024 - Marketscreener.com
Encapsulated Live Cell Market to Record Rapid Revenue Growth from 2024 to 2031 - Elektrotransports.lv
Pancreatic Cancer Treatment Market Size Worth USD 10.53 - GlobeNewswire
Pancreatic Cancer Treatment Market Size Worth USD 10.53 Billion by 2032 Driven by Rising Prevalence of Obesity, Smoking, and Alcohol Consumption | Research by SNS Insider - GlobeNewswire Inc.
Financial Analysis: PharmaCyte Biotech (OTCMKTS:PMCBD) vs. INmune Bio (NASDAQ:INMB) - Defense World
PMCB stock touches 52-week low at $1.75 amid market challenges - Investing.com Australia
500: Something went wrong - Investing.com India
PMCB stock touches 52-week low at $1.75 amid market challenges - Investing.com UK
TNF Pharmaceuticals, Inc. announced that it expects to receive $14 million in funding from PharmaCyte Biotech, Inc. - Marketscreener.com
PharmaCyte Biotech (OTCMKTS:PMCBD) Shares Down 1.9% - Defense World
Live Cell Encapsulation Market 2024 Growth Analysis by Market Es - WICZ
Live Cell Encapsulation Market 2024 Growth Analysis by Market Estimation, Manufacturers, Product Types Gross Margin and Forecast to 2030 - WICZ
Pancreatic Beta-Cell Protection Market Analysis and Revenue Prediction | ViaCyte, PharmaCyte Biotech, Boehringer ... - Economica
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Down 2.4% - Defense World
PharmaCyte Biotech (NASDAQ:PMCB) Trading Down 2.4% - Defense World
Pancreatic Cancer Market is expected to surpass USD 7,541.09 Million by 2033, growing at a 13.5% annual rate | FMI Study - Market Research Blog
Pancreatic Cancer Market is expected to surpass USD 7,541.09 Million by 2033, growing at a 13.5% ann - PharmiWeb.com
Malignant Ascites Market Report 2034: Epidemiology, Pipeline The - News Channel Nebraska
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Up 2% - Defense World
PharmaCyte Biotech (NASDAQ:PMCB) Stock Price Up 2% - Defense World
PharmaCyte Biotech's Diabetes Treatment: How Would It Work? - Yahoo Movies UK
Critical Analysis: PharmaCyte Biotech (OTCMKTS:PMCBD) vs. LENZ Therapeutics (NASDAQ:LENZ) - Defense World
MyMD Pharmaceuticals secures $7M investment from PharmaCyte Biotech - TipRanks
PharmaCyte Biotech announces $7 million strategic investment in MYMD - MSN
MyMD Pharmaceuticals Secures Strategic Investments - citybiz
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on ... - Winchester Herald Chronicle
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on ... - Business Wire
MyMD Pharmaceuticals Secures Strategic Investments - Yahoo Finance
Ascites Treatment Market Emerging Trends | Sequana Medical, BioVie, PharmaCyte Biotech - Motions Online
PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business - Simply Wall St
Femasys secures nearly $7M in funding from PharmaCyte - Mass Device
Ascites Market Exploring Market Trends and Growth: A 2030 Forecast Report | IMR Market Report - Newstrail
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology - Business Wire
PharmaCyte Biotech Announces Final Results of Tender Offer - Business Wire
PharmaCyte Biotech Announces Cash Tender Offer for up to 7750000 Shares at $3.25 Per Share - Business Wire
Trend Innovations Holding, Inc. Appoints Kenneth L. Waggoner as Chief Executive Officer - GlobeNewswire
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan - Business Wire
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value - StockTitan
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital - Business Wire
MPD Chief's proposed officers around high schools reignites debate around SROs - WMSN Fox 47 Madison
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation - Business Wire
PharmaCyte Biotech begins first phase of two-phase animal study to treat pancreatic cancer - Seeking Alpha
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study - Business Wire
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase ... - StockTitan
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites - Business Wire
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements - Business Wire
Pharmacyte Biotech Inc (NASDAQ: PMCB) Gets Ready to Resubmit Investigational New Drug (IND) to the FDA - FactsAboutCBD
'I'm hurt': Dozens gather on Madison's south side following Rittenhouse verdict - WMSN Fox 47 Madison
Pharmacyte Biotech, Inc. (NASDAQ: PMCB) Reports The First Test Results Of The Biocompatibility Studies Of Its Cypcaps™ Clinical Trial Product Candidate - BP Journal
7 Penny Stocks Waiting on the FDA for Rocket Fuel - InvestorPlace
PMCB: After Nasdaq Uplisting, PharmaCyte Biotech Looks Ready to Rumble - StockNews.com
BeyondSpring (NASDAQ: BYSI) Enter Co-development And Commercialization Agreement With Jiangsu Hengrui Pharmaceuticals - BP Journal
PharmaCyte Biotech (PMCB) Stock Price, News & Analysis - MarketBeat
PMCB PharmaCyte Biotech Inc. - Quantisnow
Troutman Pepper Advises PharmaCyte Biotech on Registered Direct Offering - Troutman Pepper
PharmaCyte Biotech plunges on $70M capital raise program announcement - Seeking Alpha
PharmaCyte Biotech Stock Skyrockets as CEO Spells Out Plans - TheStreet
Troutman Pepper Advises PharmaCyte Biotech on Follow-On Public Offering and Uplisting to Nasdaq - Troutman Pepper
PharmaCyte Biotech's stock loses more than half its value ahead of Nasdaq debut - MarketWatch
PharmaCyte Biotech (NASDAQ:PMCB) Stock Quotes, Forecast and News Summary - Benzinga
PMCBPharmaCyte Biotech, Inc. Latest Stock News & Market Updates - StockTitan
Triple Combination Shows Promising Responses in Advanced Pancreatic Cancer - Weill Cornell Medicine Newsroom
Developer of PharmaCyte Biotech’s COVID-19 Test Explains Why His Test Is So Highly Sensitive, Path to FDA EUA, and Commercialization - Marketscreener.com
Johnson & Johnson Acquires TARIS Biomedical - Contract Pharma
With Ph IIb trials planned, PharmaCyte looks to revolutionize cancer treatment - OutSourcing-Pharma.com
0.05%
4.86%
자본화:
|
볼륨(24시간):